Nonalcoholic fatty liver disease is a risk factor for large-for-gestational-age birthweight.

Abstract

OBJECTIVE:

Nonalcoholic fatty liver disease (NAFLD) is a well-recognized hepatic manifestation of metabolic disease in adults and has been associated with the development of gestational diabetes (GDM). Hepatic insulin resistance can result in increased release of glucose (from gluconeogenesis) and free fatty acids (due to enhanced lipolysis), which can lead in turn to fetal overgrowth. However, the relationship between maternal metabolic factors (such as circulating levels of triglycerides, free fatty acids [FFA], or adipokines) and excessive fetal birthweight in NAFLD has not been carefully examined. In this study, we evaluated the relationship between NAFLD and the subsequent risk of large-for-gestational-age (LGA) birthweight.

METHOD:

Singleton nondiabetic pregnant women were evaluated for the presence of fatty liver at 10-14 weeks of gestation by abdominal ultrasound. The degree of fatty liver was classified as Grade 0-3 steatosis. At the time of liver ultrasound, maternal blood was taken after fasting and measured for adiponectin and FFA. LGA was defined as birthweight >90th percentile for gestational age.

RESULTS:

A total of 623 women were included in the analysis. The frequency of LGA was 10.9% (68/623), and the frequency of NAFLD was 18.9%. The risk of LGA increased significantly in patients with Grade 2-3 steatosis in the first trimester. The relationship between Grade 2-3 steatosis and LGA remained significant after adjustment for maternal age, pre-pregnancy BMI, GDM, and maternal serum triglyceride levels. The concentration of maternal blood adiponectin at 10-14 weeks was significantly lower in cases with LGA than non-LGA, but the maternal blood FFA concentrations were not different between the groups.

CONCLUSION:

The presence of Grade 2-3 steatosis on ultrasound in early pregnancy was associated with the increased risk of delivering an LGA infant, even after adjustment for multiple confounding factors including GDM. Adiponectin may be the linking biomarker between NAFLD and LGA.

• Authors: Seung Mi Lee, Byoung Jae Kim, Ja Nam Koo, Errol R Norwitz, Ig Hwan Oh, Sun Min Kim, Sang Youn Kim, Gyoung Min Kim, Soo Heon Kwak, Won Kim, Sae Kyung Joo, Sue Shin, Chanthalakeo Vixa, Chan-Wook Park, Jong Kwan Jun, Joong Shin Park
• Journal: PloS one (PLoS One) Vol. 14 Issue 8 Pg. e0221400 ( 2019) ISSN: 1932-6203 [Electronic] United States
• PMID: 31449538 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Topics

• Adult
• Birth Weight (physiology)
• Body Mass Index
• Diabetes, Gestational (epidemiology, physiopathology)
• Female
• Fetus
• Gestational Age
• Humans
• Infant, Newborn
• Infant, Newborn, Diseases (epidemiology, physiopathology)
• Insulin Resistance (physiology)
• Non-alcoholic Fatty Liver Disease (epidemiology, physiopathology)
• Pregnancy
• Pregnancy Complications (epidemiology, physiopathology)
• Risk Factors
• Weight Gain (physiology)
• Young Adult